What it is
ChromoMap℠ is a noninvasive prenatal screen (NIPS) that provides valuable insight into fetal chromosome health as early as 10 weeks of pregnancy.
The ChromoMap PanelThe Serenity℠ Panel
The core ChromoMap panel includes Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). Optional add-on panels are also available at no additional charge.
CooperGenomics’ ChromoMap screenSerenity NIPT leverages the power of Massively Parallel Sequencing, using a signature algorithm to target and more deeply analyze fetal chromosome material. Grounded in scientific research, ChromoMap NIPS has been rigorously validated using clinical outcome performance data on over 85,000 cases, and has the lowest failure rate in the field, meaning fewer sample redraws and overall faster results to you and your patients.
Internal CooperGenomics & Illumina data
|FOR TRISOMY 21, PPV = 0.9581 AND NPV = 0.9999.|
FOR COMBINED TRISOMY 21, 13, AND 18,
PPV = 0.835 AND NPV = 0.999.
Serenity NIPT analysis is performed on-site at CooperGenomics’ UKAS ISO 15189:2012 accredited London laboratory.* Proud to be your trusted genetics partner, CooperGenomics holds worldwide certifications, licenses, and accreditations, giving you confidence in our responsible laboratory practices.
*Under certain circumstances, testing may be performed at Illumina’s US laboratory.
Reporting & Counseling
ChromoMap reports are available 3-5 business days after the sample arrives at our laboratory. Results and fetal fraction are presented clearly on the first page, and PPV is provided for all positive results.
CooperGenomics’ expert team of board-certified genetic counselors are available for you and your patients. For all patients with positive results, follow-up is carefully and expeditiously coordinated with your practice to develop a customized care plan prior to releasing the report.
Serenity NIPT reports are available 3-5 working days after the sample arrives at our laboratory. All reports include fetal fraction and clearly indicate if a chromosome abnormality was detected in the patient’s pregnancy.
CooperGenomics’ team of genetic counselors is available to guide you and your patients through all ‘Detected’ results and provide a detailed discussion of follow-up testing options.
ChromoMap NIPS is a screening test. Diagnostic tests such as amniocentesis or CVS are available to confirm results. However, because these tests are invasive, they carry a risk of complications, including miscarriage.